Financial Results for the Quarter ended June 30, 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin CompressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.3%Reaction day

₹28.98

prior close

₹29.98

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+2.6% vs market

Pharmaceuticals peers, median of 147sector-0.3%+2.7% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 2.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.0

10m

+1.0

15m

+0.8

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.3-0.3+2.6-0.3+2.7

Next day

-2.8-2.2-0.6-1.4-1.4

-1.9-3.4+1.5-2.0+0.1

-5.1-1.9-3.2-1.0-4.1

-3.9-1.6-2.3-1.0-2.9

-8.7-2.3-6.3-1.6-7.1

-10.5-3.3-7.1-3.4-7.1

15d

-0.3-5.8+5.5-5.0+4.7

+18.0-3.7+21.7-5.3+23.3

-17.5-2.4-15.1-4.2-13.3

+2.5-3.5+6.0-7.6+10.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venmax Drugs reported total revenue of ₹121.03 lakhs for Q1 FY26, jumping from just ₹13.40 lakhs in Q1 FY25, driven almost entirely by a sharp rise in revenue from operations (₹121.03 lakhs vs ₹10.40 lakhs). Profit after tax rose to ₹3.74 lakhs (EPS ₹0.071) compared to ₹1.08 lakhs (EPS ₹0.02) a year ago. Total expenses climbed to ₹117.29 lakhs, mainly on stock-in-trade purchases of ₹112.25 lakhs, which pulled the operating margin down. Cash flow from operations turned positive at ₹9.70 lakhs versus a ₹229.02 lakh outflow for the full previous year. The statutory auditor (PPKG & Co) issued an unmodified limited review report.

Likely market impact

Strong top-line growth is a positive signal for shareholders, but thin margins and a negative other equity (₹84.97 lakhs accumulated losses) suggest the company is still in an early recovery phase. Watch receivables closely as they more than doubled to ₹230.81 lakhs, which could pressure future cash flows.